20-Jul-2012 - Synthon BV

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer. Earlier this year Synthon successfully completed a Phase I clinical trial in Europe showing bio-equivalence between its trastuzumab biosimilar and Herceptin®. The company was preparing for a confirmatory Phase III trial for Europe with this compound.

Under the agreement, Watson has acquired the license to the biosimilar program and has contributed it to the Amgen/Watson biosimilars collaboration. Amgen and Watson will assume responsibility for all future development work worldwide, including Phase III clinical trials, as well as global manufacturing and commercialization. Synthon will provide transitional support as set forth in the agreement. The deal entitles Synthon to an initial payment and potentially a milestone fee and royalties on net sales. Synthon will also receive compensation for its transitional support activities under the agreement. Synthon has retained rights to move forward independently with a HER2-targeted antibody-drug conjugate (ADC) candidate using its proprietary Linker-Drug technology.

Synthon’s trastuzumab is one of the most advanced products in the company’s biopharmaceuticals pipeline. It is one of the first trastuzumab biosimilar products to have completed a Phase I trial in Europe.

Additional details of the transaction were not disclosed.

Facts, background information, dossiers
More about Synthon
  • News

    Synthon Announces Successful Outcomes from Phase III Study of Synthon’s Glatiramer Acetate

    Synthon announces that data from the open-label extension of the Phase III GATE study of the Company’s generic glatiramer acetate in patients with relapsing remitting multiple sclerosis (RRMS) demonstrate that efficacy, safety and tolerability were maintained over the entire two-year study ... more

    Antitope and Synthon announce collaboration

    Antitope Limited, an Abzena company, announced that it will collaborate with Synthon Biopharmaceuticals BV, to assess the potential immunogenicity of candidate antibodies for Synthon’s ADC programmes. Antitope will use its EpiScreen™ technology, a highly accurate and sensitive ex vivo human ... more

    Synthon and MAB Discovery sign discovery agreement

    Synthon Biopharmaceuticals BV and MAB Discovery GmbH announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company’s development of antibody-drug conjugates (ADC ... more

  • Companies

    Synthon BV

    Undertaking what others cannot or dare not. As researchers and entrepreneurs, that is clearly the path for us. In the next ten years we are determined to shape our future by extending the vertical integration of our activities, entering new markets and developing new classes of product. Sy ... more

More about Amgen
More about Watson Pharmaceuticals
  • News

    Watson Completes Actavis Acquisition

    Watson Pharmaceuticals, Inc. announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion.  The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. Watson funded ... more

    Watson Names Robert A. Stewart Senior Vice President, Global Operations

    Watson Pharmaceuticals announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, effective immediately. In this position, Mr. Stewart will have responsibility for global manufacturing, supply chain, quality and technic ... more

    Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit

    Watson Pharmaceuticals, Inc. announced a license agreement with GeneraMedix, Inc. for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection), a drug indicated for the treatment of iron deficiency anemia in hemodialysis pati ... more

  • Companies

    Watson Pharmaceuticals, Inc.

    Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical). more